Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib cerebrospinal fluid pharmacokinetics study in healthy participants
NL-OMON60113Phase 1Completed
- Sponsor
- Novartis
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of remibrutinib, sponsored by Novartis. Started Dec 2023; status: completed.
02
Drugs
remibrutinib
Beyond the preview
Go deeper on NL-OMON60113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60113.